Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Strengthening Leadership with Multimedia Announcement
Byondis B.V., an independent biotechnology company focused on the development of innovative targeted therapies for cancer, has announced a significant leadership transition with the appointment of Christoph Korpus, PhD, MBA, as its new Chief Executive Officer (CEO), effective immediately. This move marks a new chapter in the company’s evolution as it continues to strengthen its position in the competitive oncology landscape.
Christoph Korpus steps into the CEO role after serving as Chief Business Officer (CBO) since January 2025, during which time he played a key role in shaping the company’s strategic direction. He succeeds Jacques Lemmens, PhD, the founder of Byondis, who will remain actively involved with the organization as Chairman of the Board of Directors. This leadership transition reflects both continuity and forward momentum, with Korpus expected to build upon the strong foundation established under Lemmens’ leadership.
As CEO, Korpus will be responsible for overseeing the advancement of Byondis’ research and development pipeline, with a particular focus on its proprietary antibody-drug conjugate (ADC) platforms. These platforms represent a cutting-edge approach within oncology therapeutics, combining the targeting precision of monoclonal antibodies with potent cytotoxic agents designed to selectively eliminate cancer cells while minimizing damage to healthy tissue. The company’s ADC technologies are distinguished by their integration of novel payloads, advanced linker systems, and conditional activation mechanisms aimed at enhancing both efficacy and safety.
Among the company’s key innovation platforms is its cytotoxic antifolate linker-drug technology, which is designed to deliver highly potent payloads directly to tumor cells. In addition, Byondis has developed ByonGuard™, a masking technology that enables conditional activation of ADCs, allowing therapies to remain inactive until they reach the tumor microenvironment. This approach has the potential to reduce systemic toxicity and improve therapeutic windows. Another important platform, ByonBoost™, incorporates immune-stimulatory linker-drug components intended to activate the immune system in conjunction with targeted cancer cell killing, thereby creating a dual mechanism of action.
Each of these platforms has already generated a portfolio of promising drug candidates, including both lead programs and follow-on molecules. A distinguishing feature of Byondis B.V. is its fully integrated operational model, which encompasses discovery, development, and manufacturing capabilities. This end-to-end infrastructure allows the company to independently advance its lead candidates through critical stages of development while maintaining flexibility to pursue strategic collaborations. In parallel, Byondis remains open to partnerships and licensing opportunities that can further accelerate the development and commercialization of its technologies.
Christoph Korpus brings more than 15 years of diverse experience across the global biopharmaceutical industry, with expertise spanning oncology research and development, digital innovation, and business development. Prior to joining Byondis, he held a leadership role at Merck KGaA, where he served as Director of Global Business Development and Licensing in Oncology. In that capacity, Korpus led strategic partnering initiatives and negotiation teams for multiple high-profile transactions, helping to expand the company’s oncology portfolio through collaborations and licensing agreements.
During his tenure at Merck KGaA, Korpus also played a pivotal role in fostering cross-company innovation by managing global alliances that bridged commercial and development functions across multiple therapeutic areas. His experience in building and sustaining complex partnerships is expected to be a valuable asset as Byondis seeks to expand its global footprint and leverage external collaborations to complement its internal capabilities.
Commenting on the appointment, Chairman Jacques Lemmens highlighted Korpus’ contributions since joining the company and expressed confidence in his ability to lead Byondis into its next phase of growth. He noted that Korpus had been instrumental in driving the company’s transformation into a focused and fully integrated biotech organization with a strong emphasis on proprietary ADC platforms. Lemmens also emphasized Korpus’ deep understanding of the company’s technologies and their potential to address significant unmet medical needs in oncology.
For his part, Christoph Korpus described his appointment as both an honor and a responsibility, particularly at a time when the company’s strategic direction is clearly defined. He underscored his commitment to executing Byondis’ long-term vision, advancing its pipeline of innovative therapies, and fostering partnerships that can enhance growth and accelerate development timelines. Korpus also acknowledged the strong foundation established under Lemmens’ leadership, including the company’s robust capabilities in ADC discovery, development, and Good Manufacturing Practice (GMP) production.
Looking ahead, Korpus aims to leverage these capabilities to maximize the value of Byondis’ technology platforms and deliver differentiated therapies that address the limitations of existing and next-generation cancer treatments. His leadership will focus on translating the company’s scientific innovations into tangible clinical benefits for patients, while also ensuring sustainable growth through strategic collaborations and operational excellence.
In terms of academic credentials, Korpus holds a PhD from Ludwig-Maximilians-Universität Munich and the University of Connecticut. He also earned an MBA from the Kellogg School of Management and WHU-Otto Beisheim School of Management, equipping him with a strong combination of scientific and business expertise.
This leadership transition comes at a pivotal time for Byondis B.V. as it seeks to accelerate the development of its ADC pipeline and expand its role in the global oncology ecosystem. With Korpus at the helm, the company is well-positioned to advance its mission of delivering innovative, targeted therapies that have the potential to significantly improve outcomes for patients living with cancer.
About Byondis
Driven to improve patients’ lives, Byondis is an independent, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates.
Byondis’ development portfolio leverages expertise in linker-drug (LD) technology, antibody-drug conjugation, and disease biology. Byondis’ fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D, production of clinical batches of the selected product candidates, and regulatory filings which are all done in-house.
The company has a dedicated team of more than 200 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.
Source Link:https://www.businesswire.com/
